Tecovirimat - SIGA Technologies

Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246®; TPOXX

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroPharma
  • Developer Biomedical Advanced Research and Development Authority; SIGA Technologies
  • Class Antivirals; Benzamides; Indoles; Small molecules
  • Mechanism of Action Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Smallpox
  • Phase III Orthopoxvirus infections

Most Recent Events

  • 07 Feb 2018 FDA assigns target final action date of 08/08/2018 for tecovirimat for Small pox
  • 07 Feb 2018 Tecovirimat receives priority review status for Small pox in USA
  • 07 Feb 2018 The US FDA accepts NDA for tecovirimat for Small pox in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top